Schedule flexibility: Understand how injection timing shifts affect plasma concentrations for travel or lifestyle adjustments
On the right, GIP binding to a G protein-bound GIP receptor is shown (PDB 7RA3)
These are the factors that typically point toward the slower path: Prior intolerable nausea or vomiting on semaglutide, tirzepatide, or other GLP-1 medications History of GERD, gastroparesis, or functional GI disorders Lower body weight, where the effective dose-per-kilogram is relatively higher at standard doses First-time users of peptide or GLP-class medications with no tolerability baseline The slow-titration approach does not change the target dose or the expected outcomes
Both platforms provide legitimate clinical oversight
As some researchers are looking at how they can deliver GLP-1s in vivo, others are looking beyond GLP-1 peptides altogether
The study results of the studies SURPASS-1 to SURPASS-5 have been published, and the remaining studies (SURPASS-6, SURPASS-CVOT, SURPASS-J-mono, SURPASS-J-combo
